| Dr Jannie W Cheung, PHARM D | |
|
15800 Imperial Hwy, La Mirada, CA 90638-2512 | |
| (562) 902-5538 | |
| (562) 903-6517 |
| Full Name | Dr Jannie W Cheung |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 15800 Imperial Hwy, La Mirada, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235457300 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RPH45047 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jannie W Cheung, PHARM D 4028 Golden Terrace Ln, Chino Hills, CA 91709-4928 Ph: (562) 902-5538 | Dr Jannie W Cheung, PHARM D 15800 Imperial Hwy, La Mirada, CA 90638-2512 Ph: (562) 902-5538 |
News Archive
A ground breaking computer game developed by a University of Salford lecturer to help educate young South Africans about the dangers of HIV and AIDS will be piloted in July.
Sanquin Blood Supply Foundation, the Netherlands Cancer Institute, and the Netherlands Vaccine Institute announce today the launch of their joint AmpVacs project aiming at the development of a broadly protective synthetic influenza A vaccine component that in combination with classical antibody-stimulating vaccines will induce protection against future influenza A threats.
During the recent 2015 Transcatheter Cardiovascular Therapeutics Meeting held in San Francisco, CA, Medinol Ltd. continued to introduce novel stent solutions to the coronary marketplace. During a satellite symposium, "The BioNIR eDES: The Role of Uniformity in Stent Design to Minimize Restenosis", a renowned physician panel discussed the key attributes of the currently available Medinol NIRxcell CoCr Coronary Stent System and the Medinol eDES Coronary Stent System (in trials, not FDA/CE Mark approved).
CMC Biologics and OncoSynergy have entered into an agreement for process development and GMP manufacture of OS2966 – a novel potential treatment for Ebola. The investigational drug candidate, designed to inhibit a major cellular adhesion receptor (CD29) that is fundamental for progression of aggressive and resistant cancer tumors, was granted orphan drug designation by the U.S. FDA earlier this year in the treatment of glioblastoma.
Ascendant Solutions, Inc. today announced its results for the first quarter of fiscal 2010. The Company reported consolidated net income of $395,000 for the fiscal quarter ended March 31, 2010, compared to net income of $203,000 in 2009, resulting in net income per share ("EPS") of $0.02 compared to net income per share of $0.01.
› Verified 9 days ago
Luis Antonio Vidaurrazaga Jr., Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12049 Penford Dr, La Mirada, CA 90638 Phone: 310-908-5817 | |
Yisu Kim, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 13208 La Jolla Cir # 308-e, La Mirada, CA 90638 Phone: 714-323-7863 | |
Sora Hwang, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 8161 Barrington Dr, La Mirada, CA 90638 Phone: 562-418-0111 | |
Jean Hee Kim-hossein, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 14885 Telegraph Rd, La Mirada, CA 90638 Phone: 562-777-3405 | |
Joy Chang, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 14885 Telegraph Road, La Mirada, CA 90638 Phone: 562-777-3405 Fax: 562-777-3415 | |
Minah Rhee, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 16434 Visions Dr, La Mirada, CA 90638 Phone: 562-261-3512 |